Laboratórios Basi is a Pharmaceutical company, whose origin dates back to 1956.
It was acquired in 2007 by FHC Farmacêutica, time from which it underwent a very relevant set of investments, which allowed it to consolidate its brand in the national and international market, while increasing from just over 10 employees to the current 280.
The FHC Group is present in the entire chain of the Medicine and Laboratórios Basi plays a central role in the corporate strategy, very focused on the areas of production, marketing and research & development of a wide range of pharmaceutical products in different therapeutic areas.
The bet of the Group in the creation of a solid industrial arm, led, in 2012, to the construction of the Quality Control Laboratory and of a new manufacturing unit dedicated to the development and manufacturing of liquid and semi-solid pharmaceutical forms, including oral solutions and suspensions, syrups, products for skin application, creams, gels, ointments and suppositories.
In 2017, it began the construction of a new parenteral unit with a line for SVP (small volume parenterals) in glass and a line for LVP (large volume parenterals) in polypropylene bottles.
Based in Mortágua, in the central region of Portugal, Laboratórios Basi industrial complex currently occupies an area of 25,000 m2, in a total of 150,000 m2 of available area, a fact that evidences the growth strategy, supported by the reinforcement and enhancement of the current units, while seeking to be one step ahead of its time in the areas of research, development and innovation.
To this end, we highlight the last major project, the Small and Large Volume Injectable Unit, in an investment of €40,000,000, which has become a true example of the application of the SMART FACTORY 4.0 concepts in the areas of automation, robotics and connectivity, whose equipment and systems are equipped with State-of-the-art technology, which allow reaching very high levels of efficiency with minimal environmental impact associated.
Realizing that the sharing of knowledge substantially increases the possibility of achieving success, the FHC Group, also via Laboratórios Basi, assumed Research & Development as one of the main pillars of its activity through the expansion of multiple partnerships with other research and development companies, R&D centres and Universities in various scientific areas, where we participate in several masters and doctoral programmes in company.
This way, we guarantee that the projects benefit from the most recent scientific developments and techniques, a commitment that has been recognized by the National Innovation Agency with the attribution of incentives to the several on-going projects.
As one of the leading pharmaceutical companies in Portugal, we are more committed than ever in reinforcing our investment in solutions that will benefit the response to several diseases, with emphasis on biological/biotechnology and oncology products.
Also in the field of oncology, Laboratórios Basi and the start-up TargTex closed an investment agreement of 2 million euros for the development of a new treatment for brain tumours, which will be channelled towards the conclusion of the Research & Development phase and to initiate the formal preclinical studies necessary to apply for authorization to perform the first human trials.
We believe that our investment in an innovative company like TargTex will accelerate the availability of a new treatment for cancer patients.
In line with these efforts, Laboratórios Basi promoted a new partnership with the collaborative innovation consultant Beta-i, whose purpose is to launch the Basi Innov.Bio.Tech project, an innovation program that aims to challenge start-ups from around the world to join efforts in developing pilot projects capable of creating new medicines and therapies in these key areas for the lives of so many patients, such as oncology and immunotherapy.
FHC Group and Laboratórios Basi have the ambition to contribute in an increasingly significant way in the area of product development, research and innovation. Aware of the central role we play, we are pleased to see our project for the new R&I facilities for the manufacture of biological products taking the first steps towards its implementation.